Kwality Pharmaceuticals Intrinsic Value
Kwality Pharmaceuticals (KPL) median intrinsic value is ₹1388.48 from 9 valuation models (range ₹694–₹2146), vs current price ₹3471.20 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. See KPL book value comparison to compare market price against book value per share.
KPL Valuation Methods Summary — DCF, Graham Number & P/E
Kwality Pharmaceuticals intrinsic value across 9 models vs current price ₹3471.20 — upside/downside and value range per method. For current market price and key ratios, visit Kwality Pharmaceuticals screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2146.32 | ₹1717.06 - ₹2575.58 | -38.2% | EPS: ₹97.56, Sector P/E: 22x |
| Book Value Method | asset | ₹694.24 | ₹624.82 - ₹763.66 | -80.0% | Book Value/Share: ₹330.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1264.00 | ₹1137.60 - ₹1390.40 | -63.6% | Revenue/Share: ₹632.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1600.00 | ₹1440.00 - ₹1760.00 | -53.9% | EBITDA: ₹160.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1388.48 | ₹1110.78 - ₹1666.18 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1041.36 | ₹937.22 - ₹1145.50 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1507.30 | ₹1356.57 - ₹1658.03 | -56.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1735.60 | ₹1562.04 - ₹1909.16 | -50.0% | ROE: 30.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1041.36 | ₹937.22 - ₹1145.50 | -70.0% | EPS: ₹97.56, BVPS: ₹330.00 |
KPL Intrinsic Value vs Market Price — All Valuation Models
Kwality Pharmaceuticals fair value range ₹694–₹2146 vs current market price ₹3471.20 across 9 valuation models. Check Kwality Pharmaceuticals networth to track the company's total market size over time.
KPL Intrinsic Value Analysis — Undervalued or Overvalued?
Kwality Pharmaceuticals median intrinsic value ₹1388.48, current price ₹3471.20 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of KPL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kwality Pharmaceuticals (KPL) is ₹1388.48 (median value). With the current market price of ₹3471.20, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹694.24 to ₹2146.32, indicating ₹694.24 - ₹2146.32.
Is KPL undervalued or overvalued?
Based on our multi-method analysis, Kwality Pharmaceuticals (KPL) appears to be trading above calculated value by approximately 60.0%.
KPL Financial Health — Key Ratios vs Industry Benchmarks
Kwality Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.97 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 30.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.07x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KPL Cash Flow Quality — Operating & Free Cash Flow
Kwality Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹17 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹53 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹43 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹41 Cr | ₹17 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹61 Cr | ₹30 Cr | Positive Free Cash Flow | 7/10 |